# Tom Lemberg

> Tom Lemberg is the Founder & CEO of Curebase, a San Francisco-based decentralized clinical trial platform that has enrolled over 60,000 patients across 60+ studies. A Harvard-trained computer scientist and molecular biologist, Lemberg built Curebase from his couch in 2017, joined Y Combinator in 2018, and raised $59M to transform how clinical trials work - letting patients participate from home and bringing their own doctors into the research process. Named to Forbes 30 Under 30 in 2022, he's on a mission to make clinical trials accessible to any patient, anywhere.

- **Role:** Founder & CEO at Curebase
- **Organizations:** Curebase, Y Combinator (S18), Syapse, Athenahealth
- **From:** Bloomfield Hills, Michigan, United States
- **Nationality:** American
- **Education:** High School Diploma, Cranbrook Kingswood, A.B. in Computer Science and Molecular & Cellular Biology, Harvard University
- **Known for:** Named to Forbes 30 Under 30 (2022) for healthcare innovation, Raised $59M+ in total funding (seed, Series A, Series B), Grew Curebase from 0 to 125+ employees

## Career timeline

- **2011-2013** — Teaching Fellow at Harvard - usable interactive systems design and mobile application development
- **2012-2013** — Research internships at Wyss Institute for Biologically Inspired Engineering (Harvard) and Amazon
- **2014-2015** — Software Development Engineer at Athenahealth
- **2015-2017** — Product Manager and Customer Solutions Software Engineer at Syapse, San Francisco
- **2017** — Founded Curebase; bought curebase.com domain for $3,000 out of pocket; built the tech solo from his couch
- **2018** — Joined Y Combinator (S18 batch); raised $2.5M seed funding
- **2020** — Launched CURE-19, a platform for at-home COVID-19 clinical trials
- **2021** — Raised $15M Series A led by GGV Capital
- **2022-05** — Raised $40M Series B led by Industry Ventures, with strategic investment from Gilead Sciences; named to Forbes 30 Under 30

## Achievements

- Named to Forbes 30 Under 30 (2022) for healthcare innovation
- Raised $59M+ in total funding (seed, Series A, Series B)
- Grew Curebase from 0 to 125+ employees
- Enrolled 60,000+ patients in 60+ decentralized clinical studies
- Achieved 97% patient satisfaction rating in pivotal FDA-cleared study
- 32% greater diversity among trial participants vs. traditional trials
- 300-400% year-over-year revenue growth
- Y Combinator S18 alumnus
- Onboarded 100+ community physicians as first-time clinical trial researchers
- Secured strategic investment from global pharma company Gilead Sciences
- Pioneered the 'Bring Your Own Physician' (BYOP) model for decentralized trials

## Latest updates

- **2022-05** — Closed $40M Series B round led by Industry Ventures with strategic investment from Gilead Sciences
- **2022-01** — Named to Forbes 30 Under 30 list for healthcare innovation
- **2020-05** — Launched CURE-19 platform for remote COVID-19 clinical trial participation across the US

## Links

- Website: https://curebase.ai
- LinkedIn: http://www.linkedin.com/in/tom-lemberg-3270a426
- Twitter/X: https://twitter.com/CurebaseDCT
- Facebook: https://facebook.com/curebase2020/?ref=page_internal

---

Profile page: https://yespress.io/tom-lemberg
Published by YesPress — https://yespress.io
Last updated: 2026-05-06